A fas gene polymorphism influences herpes simplex virus type 2 infection in South African women

Journal of Medical Virology

Volumn 82, Issue 12, 2010, Pages 2082-2086

  Chatterjee, Koushik ^a   Dandara, Collet ^b   Gyllensten, Ulf ^c   Van Der Merwe, Lize ^d,e   Galal, Ushma ^d   Hoffman, Margaret ^a   Williamson, Anna Lise ^a,f  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UPPSALA UNIVERSITY   (Sweden)

^d SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^e UNIVERSITY OF THE WESTERN CAPE   (South Africa)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Apoptosis; Fas; HSV; Polymorphism

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ADULT; AFRICA; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; INFECTION RISK; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; PROTEIN ANALYSIS; VIRUS DETECTION;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIGENS, CD95; APOPTOSIS; CASE-CONTROL STUDIES; FAS LIGAND PROTEIN; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HERPES SIMPLEX; HERPESVIRUS 2, HUMAN; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; SOUTH AFRICA;

HUMAN HERPESVIRUS 2; SIMPLEXVIRUS;

EID: 78049400346     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21926     Document Type: Article

References (20)

1. Carter CJ. 2008. Interactions between the products of the Herpes simplex genome and Alzheimer's disease susceptibility genes: Relevance to pathological-signalling cascades. Neurochem Int 52: 920-934.
2. Chatterjee K, Engelmark M, Gyllensten U, Dandara C, van der Merwe L, Galal U, Hoffman M, Williamson AL. 2009. Fas and FasL gene polymorphisms are not associated with cervical cancer but differ among Black and Mixed-ancestry South Africans. BMC Res Notes 2: 238.
3. Dobbs ME, Strasser JE, Chu CF, Chalk C, Milligan GN. 2005. Clearance of herpes simplex virus type 2 by CD8+ T cells requires gamma interferon and either perforin- or Fas-mediated cytolytic mechanisms. J Virol 79: 14546-14554.
4. Farre L, Bittencourt AL, Silva-Santos G, Almeida A, Silva AC, Decanine D, Soares GM, Alcantara LC, Jr., Van DS, Galvao-Castro B, Vandamme AM, Van WJ. 2008. Fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia. J Leukoc Biol 83: 220-222.
5. Green J, Britten N. 1998. Qualitative research and evidence based medicine. BMJ 316: 1230-1232.
6. Heldwein EE, Krummenacher C. 2008. Entry of herpesviruses into mammalian cells. Cell Mol Life Sci 65: 1653-1668.
7. Hogrefe W, Su X, Song J, Ashley R, Kong L. 2002. Detection of herpes simplex virus type 2-specific immunoglobulin G antibodies in African sera by using recombinant gG2, Western blotting, and gG2 inhibition. J Clin Microbiol 40: 3635-3640.
8. Kanemitsu S, Ihara K, Saifddin A, Otsuka T, Takeuchi T, Nagayama J, Kuwano M, Hara T. 2002. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol 29: 1183-1188.
9. Lai HC, Sytwu HK, Sun CA, Yu MH, Yu CP, Liu HS, Chang CC, Chu TY. 2003. Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer 103: 221-225.
10. Lekstrom-Himes JA, Hohman P, Warren T, Wald A, Nam JM, Simonis T, Corey L, Straus SE. 1999. Association of major histocompatibility complex determinants with the development of symptomatic and asymptomatic genital herpes simplex virus type 2 infections. J Infect Dis 179: 1077-1085.
11. Novak N, Peng WM. 2005. Dancing with the enemy: The interplay of herpes simplex virus with dendritic cells. Clin Exp Immunol 142: 405-410.
12. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. 2002. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70: 425-434.
13. Shapiro S, Rosenberg L, Hoffman M, Kelly JP, Cooper DD, Carrara H, Denny LE, du Toit G, Allan BR, Stander IA, Williamson AL. 2003. Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives (South Africa). Cancer Causes Control 14: 485-495.
14. Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, Skibola CF, Smith MT, Morgan GJ. 2003. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 63: 4327-4330.
15. Sieg S, Yildirim Z, Smith D, Kayagaki N, Yagita H, Huang Y, Kaplan D. 1996. Herpes simplex virus type 2 inhibition of Fas ligand expression. J Virol 70: 8747-8751.
16. Weiss H. 2004. Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes 11: 24A-35A.
17. Wu J, Metz C, Xu X, Abe R, Gibson AW, Edberg JC, Cooke J, Xie F, Cooper GS, Kimberly RP. 2003. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: A candidate background gene in African American systemic lupus erythematosus patients. J Immunol 170: 132-138.
18. Zanone PB, Riva A, Nasi M, Cicconi P, Broggini V, Lepri AC, Mologni D, Mazzotta F, Monforte AD, Mussini C, Cossarizza A, Galli M. 2008. Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. AIDS 22: 1769-1778.
19. Zhang J, Xu X, Liu Y. 2004. Activation-induced cell death in T cells and autoimmunity. Cell Mol Immunol 1: 186-192.
20. Zhang Z, Wang LE, Sturgis EM, El-Naggar AK, Hong WK, Amos CI, Spitz MR, Wei Q. 2006. Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res 12: 5596-5602.